Get Live Data

The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

  2. Media
  3. Poolbeg Pharma: Further data shows POLB001 potential in cancer CRS

Poolbeg Pharma: Further data shows POLB001 potential in cancer CRS

17th January 2024
Share Views
Runtime 01:26

Key highlights from today's POLB RNS include:

- Efficacy is demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model

- New data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS.

Read the full RNS here.

Poolbeg CEO Jeremy Skillington gave a POLB 001 update & explained how they use AI to speed discovery

1st March 2023

Four CEO's present on London South East 8.11.2022: ValiRx, Poolbeg Pharma, enCore Energy, Goldplat

10th November 2022

Jeremy Skillington expects strong newsflow in the next few months for Poolbeg Pharma

9th November 2022

Related Shares

Poolbeg Pharma (POLB)
11.25 (-0.55 / -4.66%)
11.10 - 11.40
Back to Media

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.